Atrakuryum etkileşimleri
nöromüsküler bloker sınıfından Atrakuryum için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 64 belgelenmiş etkileşim var: 8 majör, 33 orta, 21 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 2 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.
Etikete göre etkileşimler
Majör etkileşimler (8)
Use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol. (Atrakuryum etiketi, Kontrendikasyonlar)
Avoid concomitant use with neuromuscular blocking agents. (Kinin etiketi, Uyarılar ve önlemler)
The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (Neomisin etiketi, Kutulu uyarı)
During therapy with ZEMDRI, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients, such as patients with underlying neuromuscular disorders (including myasthenia gravis) or in patients concomitantly receiving neuromuscular blocking agents [see Warning and Precautions (5.3) ] . (Plazomisin etiketi, Kutulu uyarı)
In the case of life-threatening muscle rigidity, a rapid onset neuromuscular blocker or naloxone may be administered. (Remifentanil etiketi, Uyarılar ve önlemler)
Rocuronium Bromide Injection is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents [see Warnings and Precautions ( 5.2 )] . (Rokuronyum etiketi, Kontrendikasyonlar)
- SugammadeksMajör
Reversal of Neuromuscular Blocking Agents Other Than Rocuronium or Vecuronium Do not use BRIDION to reverse blockade induced by nonsteroidal neuromuscular blocking agents such as succinylcholine or benzylisoquinolinium compounds. (Sugammadeks etiketi, Uyarılar ve önlemler)
Atracurium should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block. (Atrakuryum etiketi, İlaç etkileşimleri)
Orta düzey etkileşimler (33)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (Atrakuryum etiketi, Uyarılar)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Myopathy Patients receiving corticosteroids, including EMFLAZA, and concomitant therapy with neuromuscular blocking agents (e.g., pancuronium) or patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) may be at increased risk of developing acute myopathy. (Deflazakort etiketi, Uyarılar ve önlemler)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
Neuromuscular Blocking Agents Anesthetic concentrations of desflurane at equilibrium (administered for 15 or more minutes before testing) reduced the ED 95 of succinylcholine by approximately 30% and that of atracurium and pancuronium by approximately 50% compared to N 2 O/opioid anesthesia (see Table 4). (Desfluran etiketi, İlaç etkileşimleri)
• Risks of Skeletal Muscle Rigidity and Skeletal Muscle Movement : Manage with neuromuscular blocking agent. (Fentanil etiketi, Uyarılar ve önlemler)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (Atrakuryum etiketi, Uyarılar)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
• Neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. (Klindamisin etiketi, İlaç etkileşimleri)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Drug Interactions Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; therefore, it should be used with caution in patients receiving such agents. (Linkomisin etiketi, İlaç etkileşimleri)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (Atrakuryum etiketi, Uyarılar)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Piperacillin and Tazobactam for Injection and Sodium Chloride Injection may prolong the neuromuscular blockade of vecuronium and other non-depolarizing neuromuscular blockers. (Piperasilin ve tazobaktam etiketi, İlaç etkileşimleri)
Depolarizing neuromuscular blocking agents: Increased effect. (Piridostigmin etiketi, İlaç etkileşimleri)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
When used to supplement alfentanil-N 2 O anesthesia, sevoflurane and isoflurane equally potentiate neuromuscular block induced with pancuronium, vecuronium or atracurium. (Sevofluran etiketi, İlaç etkileşimleri)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (Atrakuryum etiketi, Uyarılar)
If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (Atrakuryum etiketi, İlaç etkileşimleri)
Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (Atrakuryum etiketi, İlaç etkileşimleri)
Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (Atrakuryum etiketi, Uyarılar)
Neuromuscular Blocking Agents Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). (Verapamil etiketi, İlaç etkileşimleri)
Minör değinmeler (21)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (Digoksin etiketi, İlaç etkileşimleri)
- DoksapramMinör
In patients who have received neuromuscular blocking agents, doxapram may temporarily mask the residual effects of these drugs. (Doksapram etiketi, İlaç etkileşimleri)
ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (Atrakuryum etiketi, Uyarılar)
Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. (Fenitoin etiketi, İlaç etkileşimleri)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (Atrakuryum etiketi, Uyarılar)
Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. (Fosfenitoin etiketi, İlaç etkileşimleri)
ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (Atrakuryum etiketi, Uyarılar)
N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (Karbamazepin etiketi, İlaç etkileşimleri)
ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (Atrakuryum etiketi, Uyarılar)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (Atrakuryum etiketi, Uyarılar)
Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (Atrakuryum etiketi, Uyarılar)
Common Neuromuscular Blocking Agents DIPRIVAN does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants). (Propofol etiketi, İlaç etkileşimleri)
ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (Atrakuryum etiketi, Uyarılar)
Anlamlı etkileşim olmadığı bildirilenler (2)
Neuromuscular Blockers In one study of 10 healthy adult volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration. (Deksmedetomidin etiketi, İlaç etkileşimleri)
Alfentanil and Atracurium Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. (Ondansetron etiketi, İlaç etkileşimleri)
Kullandığınız her şeyi Atrakuryum ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.
Sorgulama aracında açTıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.